Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.38
- Piotroski Score 2.00
- Grade Neutral
- Symbol (STSA)
- Company Satsuma Pharmaceuticals, Inc.
- Price $1.10
- Changes Percentage (0%)
- Change -$0
- Day Low $1.10
- Day High $1.10
- Year High $8.08
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
- Last Earnings 03/19/2014
- Ex-Dividend for 5/16 Dividend 03/28/2014
- Dividend Payable 04/15/2014
- Today N/A
- Next Earnings (Estimated) 08/07/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.99
- Trailing P/E Ratio -0.55276381909548
- Forward P/E Ratio -0.55276381909548
- P/E Growth -0.55276381909548
- Net Income $-69,163,000
